December 10-13, 2022; New Orleans, Louisiana
The combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved a high CR rate at the end of treatment with low incidence of peripheral neuropathy and no episodes of febrile neutropenia.